UMAN interleukin (IL)-13, a polypeptide of 1 12 amino acids with a molecular mass of 12.4 k D , is encoded by a member of the granulocyte-macrophage colony-stimulating factor (GM-CSF), L-5, and IL-4 gene ~luster."~ IL-13 is produced by TH2 lymphocytes in the mouse, and human IL-13 shares with two other TH2-derived cytokines (IL-4 and IL-10) the capacity to inhibit cytokine synthesis by activated monocyte^.^-^ Moreover, IL-13 is an essential cytokine in the control of B-cell activation.2.' IL-13 enhances the expression of major histocompatibility complex (MHC) class I1 antigens on resting B cells and stimulates B-cell proliferation induced by anti-Ig or anti-CD40 antibodies or by Cos cells transfected with CD40 ligand. In addition, IL-13 induces IgG4 and IgE synthesis by germ line transcription and CD23 expression by mature2.' and immature human normal B cells.7 Despite similarities in their effects on normal human B cells, the functions of IL-4 and IL-13 are not identical: IL-13, in contrast with IL-4, has no proliferative effect on activated T cells or T cell
Although the IL-13 receptor (IL-13R) has not been fully characterized, recent results have shown that IL-4R and IL-13R are distinct but functionally IL4R a chain is a functional component of the IL-13R." The IL4R and IL-13R appear to share a common subunit, important for signal transduction, and the yc chain of the IL-2R was proposed to be this shared subunit. In fact, yc chain does not actively participate in the IL-13-induced signaling pathway."."
B chronic lymphocytic leukemia (B-CLL) is characterized in vivo by the accumulation of slow-dividing and long-lived monoclonal CD5+ B cells. B-CLL cells as normal B cells express surface Igs and CD40 but display a heterogeneous pattern of growth response to different cytokines, depending on the signal of acti~ation.'~"~ In vitro, B-CLL cells enter into spontaneous apoptosis, which is downregulated by IL-4, interferon (1FN)-y, or IFN-a. '9-23 Among the different cytokines, IL-4 exhibits the unique property of inhibiting IL-2-induced normal and B-CLL cell proliferati~n.~~"~ Because IL-13 shares many biologic functions with IL-4, this study was performed to examine the effects of IL-13 on B-CLL cells. B cells were cultured in RPM1 1640 supplemented with 2% selected heat-inactivated fetal calf serum (FCS), 2 mmol/L gentamine, 100 U/mL penicillin, 100 pglmL streptomycine, 2-mercaptoethanol (2-ME; 0.5 X IO-' mom), all from Gibco Laboratories (Grand Island, NY). For surface CD23 and soluble CD23 induction experiments, B-CLL cells (2 X 106/mL) were cultured for 48 hours in the absence of stimulating agent or in the presence of IL-4 (10 n g h L ) or IL-13 (10 to 100 ng/mL). At the end of the culture period, cells were stained with FITC-anti-CD23 MoAb and analyzed using a FACScan flow cytometer. Soluble CD23 (sCD23) was tested in parallel in culture supernatants, For proliferation assays, purified B cells (2 X 105 cells per well) were cultured in 96-well plates (Costar, Cambridge, MA) in a final volume of 0.2 mL. Cytokines or Bcell polyclonal activators (insolubilized anti-mu antibody, anti-CD40 MoAb) were added at the onset of the culture in the one-step assay. In some experiments (two-step assays), B cells were first preincubated for 48 hours alone or with anti-mu antibody or anti-CD40 MoAb and then stimulated with interleukins. Cells were cultured for 2 to 6 days. DNA synthesis was measured using ('H)-thymidine incorporation. Results are expressed as counts per minute (cpm) and are means 2 SD from triplicate cultures.
IL-13 INHIBITORY EFFECT ON B-CLL CELLS 023
Assay for CD23 production. B-CLL cells (2 X 10h/mL) were cultured for 24 to 48 hours in the absence or the presence of different activating signals and cytokines. Production of CD23 (pgImL) was measured using a specific enzyme-linked immunosorbent assay (ELISA; Binding Site, San Diego, CA).
Defenninafion of cell viability and apoptosis. B-CLL cell viability was determined every day by the trypan blue exclusion method. Apoptosis was determined by DNA labeling and flow cytometric analysis. Hypodiploid DNA was analyzed by flow cytometry according to Fried et akZ9 Briefly, cells (1.5 X IO6) were washed in PBS and resuspended in 1.5 mL hypotonic fluorochrome solution (50 p g h L propidium iodide in 0.1% sodium citrate plus 0.1 % Triton X-100; (Sigma, St Louis, MO). Samples were placed at 4°C in the dark before flow cytometric analysis of propidium iodide (PI) fluorescence of individual nuclei using a FACScan flow cytometer, as described by Nicoletti et al. 30 Cellular debris was excluded from analysis by raising the forward scatter threshold, and the DNA content of intact nuclei was registered on a logarithmic scale. Apoptotic cell nuclei having hypodiploid DNA emitting fluorescence in channels 10 to 200 were enumerated as a percentage of the total population. In some experiments, apoptosis was measured in parallel by a DNA fragmentation assay, as previously described." RESULTS IL-13 enhances sulface CD23 expression and induces sCD23 secretion in B -C U cells. To examine the capacity of IL-13 to exert an influence on the early activation steps of B-CLL cells, we studied the effects of IL-13 on CD23 expression on B-CLL cells (Table 2 ). Surface CD23 expression on B cells was measured by FACS analysis on freshly isolated B-CLL cells and after a 48-hour incubation period with medium, IL-4, or L-13. As previously described, leukemic B cells partially lost the expression of surface CD23 during the culture in the absence of cytokine. Both E -4 and IL-13 were able to restore expression of surface CD23 on leukemic B cells as measured by the proportion of CD23-positive cells as well as the mean fluorescence intensity (MFI) of the fluorescence histogram. The upregulation of CD23 expression induced by IL-13 was observed with 100 ng/mL of IL-13 for 2 X lo6 B-CLL cells per culture. Interestingly, IL-13 enhances CD23 expression by B-CLL cells, whatever the level of constitutive CD23 expression. The differential effects of IL-13 on CD23-and CD23+ B-CLL cells were not fully examined in this work. We then examined the capacity of IL-13 to modulate the secretion of CD23 in 48-hour B-CLL culture supernatants. In the absence of stimulus, no secretion of sCD23 was observed. IL-13 induced a significant release of sCD23, indicating that the accumulation of surface CD23 was not due to inhibition of CD23 cleavage (Table 2) . IL-13 is not a growth factor for B-CLL cells. Purified B-CLL cells were cultured alone or in the presence of different cytokines (IL-2, IL-4, IL-13), and DNA synthesis was measured by (3H)-thymidine incorporation on day 3 (Table 3 ).
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From B cells from 4 of 12 patients responded spontaneously to IL-2 in the absence of preactivation signal (patients 3, 8, 9, and 11). L 1 3 (from 1 to 200 ng/mL) did not spontaneously stimulate DNA synthesis in B-CLL cells from these 12 patients. In anti-mu-stimulated B-CLL cells, IL-2 (10 to 100 U/mL) induced a significant DNA synthesis in most patients (1 1 of 12). IL-4 (10 ng/mL) was able to support proliferation of anti-mu-activated B cells in only one patient (patient 2). IL-13 (1 to 200 ng/mL) did not exhibit a proliferative effect on anti-mu-activated B-CLL cells from all the 12 patients, whatever the respective effect of IL-2 or IL-4. This lack of effect of IL-13 was observed in B-cell cultures from day 1 to day 5. Moreover, IL-13 did not enhance DNA synthesis in B-CLL cells preincubated with anti-mu antibody for 48 hours (results not shown). B-CLL cells can be stimulated through ligation of CD40 antigen by the anti-CD40 MoAb 28-5. 15 In the presence of anti-CD40 MoAb (2 pg/mL), B-CLL cells from only 1 of 12 patients (patient 8) responded to IL-2 (100 U). In contrast, IL-4 (10 ng/mL) induced a strong proliferation in anti-CD40-stimulated B-CLL cells from 6 of 12 patients. IL-13 (10 to 200 ng/mL) did not induce DNA synthesis in anti-CD40-stimulated B cells (Table 3 ). In summary, IL-13 is not a growth factor for B-CLL cells, whatever the signaling pathway used to activate B-CLL cells.
IL-13 inhibits IL-2-induced activation of B-CLL cells. IL-4 can provide a negative signal on IL-2-stimulated B-CLL cells.26 We tested whether IL-13, although devoid of growth factor activity by itself, might interfere with the responsiveness of B-CLL cells to different lymphokines.
B-CLL cells proliferated in the presence of anti-mu plus IL-2 in 11 patients (Table 3) . IL-13, when added at the onset of the culture, significantly inhibited the DNA synthesis of anti-mu-plus IL-2-stimulated B-CLL cells. This effect was observed from day 2 to day 6 in 10 of these 11 patients (mean suppression, 72% ? 13%; Fig 1) . The inhibitory effect of IL-13 was observed, regardless of the magnitude of the response to IL-2, with a dose ranging from 10 to 100 ng/ mL of IL-13 (Fig 2) .
B-CLL cells from four patients responded spontaneously to IL-2; IL-2 alone induced a moderate DNA synthesis, and this response was fully inhibited by IL-13 (100 ng/mL; Table  4 ). When B-CLL cells were stimulated with the anti-CD40 MoAb 28-5, cells from only one patient (patient 8) responded to the stimulation given by anti-CD40 MoAb and IL-2 (1 00 U/mL). In contrast, IL-4 (10 ng/mL) induced a strong DNA synthesis in anti-CD40-stimulated B-CLL cells from 6 of 12 patients. IL-13 (100 ng/mL) inhibited the proliferation of the anti-CD40-plus IL-2-stimulated cells, but had no inhibitory effect on the proliferation of the anti-CD40-plus B-CLL cells (2 x lo6 cells per well) were stimulated with anti-mu antibody (2 pg/mL) or anti-CD40 MoAb (2 pg/mL) and cultured in the presence of IL-2 (100 U/mL), IL-4 (10 ng/mL), or IL-13 (100 ng/mL). Thymidine incorporation was measured on day 3. For each patient, one representative experiment is given. B-CLL cells stimulated with anti-mu antibody or anti-CD40 MoAb alone did not exhibit significant proliferation (less than twice the baseline). IL-4-stimulated cells (Table 4) . Collectively, these findings indicate that IL-13 specifically inhibits IL-2 responsiveness of B-CLL cells, activated either spontaneously or through crosslinking of surface Igs or ligation of CD40 antigen.
In most experiments, the effects of IL-4 (10 to 100 ng/ mL) was studied in parallel. IL-4 exhibited a strong inhibitory effect on anti-mu-plus IL-2-stimulated B-CLL cells, Figs 1 and 2 ). In addition, a neutralizing rabbit polyclonal anti-IL-4 antibody (2 pg/mL) completely blocked the IL-4 inhibitory effect. The same anti-IL-4 neutralizing antibody did not antagonize the inhibitory effect of IL-13 ( Table 5 ). suggesting that IL-13 inhibits the IL-2-stimulated B-CLL cells in an IL-4-independent fashion. IL-13 protects B-CLL cells from apoptosis. When B-CLL cells were cultured in vitro for 2 to 3 days, we observed a marked decrease in cell viability (as measured by trypan blue exclusion). B-CLL cells died of apoptosis characterized by chromatin condensation, which can be measured by flow cytometric analysis hypodiploid DNA peak. A 24-hour CUI- ture was sufficient to promote significant apoptosis of B-CLL cells, which reached a maximum on days 3 to 4 of culture with a magnitude quite different from one patient to another. In contrast, in the presence of IL-13 (200 ng/mL) on day 4 only 32% 2 12% of B-CLL cells exhibited apoptotic nuclei as compared with 68% 2 24% in control cultures (mean t SD in the I O patients tested). The protective effect of IL-13 on spontaneous apoptosis (defined as at least a 50% reduction of spontaneous apoptosis) was observed in 8 of the IO patients studied (Fig 3) . The protective effect of IL-13 was dose-dependent (Fig 4) and reproducible at 100 to 200 ng/mL concentration and was observed from day 2 to day 6 of B-CLL cultures. IL-4 strongly inhibited spontaneous apoptosis at a dose ( I 0 ng/mL) lower than that required for IL-13 (200 ng/mL), and the IL-4-induced protection was observed in all the patients tested.
B-CLL cells, CD23 antigen rapidly disappears from the Bcell membrane in short-term cultures, and CD23 expression depends on several cytokines, including IL-4.I4 IL-13 induces the reexpression of surface CD23 on B-CLL cells in cultures. It does not act by stabilizing the CD23 molecule on the cell surface, nor does it inhibit the shedding of sCD23. It induces an important secretion of sCD23, suggesting that IL-I3 signaling of B-CLL cells activates CD23 gene expression. Interestingly, IL-I 3 enhances surface CD23 expression and sCD23 production by B-CLL cells with low or high constitutive CD23 expression but does not induce CD23-negative expression in CD23-negative B cells (results not shown). 
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DISCUSSION
In this report, we show that IL-13 exhibits two main activities on B-CLL cells: inhibition of IL-2-induced proliferation and partial protection from spontaneous apoptosis.
B-CLL cells constitute a unique model to study the effects of a new cytokine on homogeneous monoclonal B-cell populations arrested in vivo at the intermediate stage of the differentiation but, in most cases, still sensitive in vitro to signaling by cytokines.'d.'x Interestingly, IL-13 acts on different stages of the maturation pathway on these monoclonal B cells. In " , . , -, -. -. -. 
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In contrast with its effect on the early phase of activation, IL-13 does not exhibit a growth-stimulating activity on B-CLL cells. IL-13, even at a 200-ng/mL concentration, does not induce DNA synthesis in unstimulated B-CLL cells. Moreover, IL-13 has no growth stimulatory activity on B-CLL cells activated either through crosslinking of sIgs or ligation of CD40,3' even when the B-CLL cells proliferate spontaneously in the presence of IL-2 or IL-4. This lack of response is not due to a delayed peak of DNA synthesis from day 2 to day 10 and is not associated with a terminal differentiation. In normal anti-mu-stimulated B cells, IL-13 induces a significant DNA synthesis that is less pronounced than that induced by IL-4.2,3,6 Thus, IL-13 exhibits a distinct functional growth activity on normal and neoplasic B cells. This could be linked to abnormal signal transduction due to the malignant transformation or could indicate a different responsiveness of the normal B-cell subset from which B-CLL cells arise. However, the last hypothesis is improbable as IL-13 predominantly acts on sIg D+ normal B cells, also present in B-CLL cells, and exhibits a growth activity on normal purified CD5+ B cells.6 Recently, Fluckiger et a13' have shown that IL-13 upregulates CD23 expression but also induces DNA synthesis in B-CLL cells, in contrast with our results. However, it should be mentioned that the growth activity of IL-13 was weak, was found in two of six patients, was measured on day 7, and was only observed when B-CLL cells were cultured with anti-CD40 MoAb 89 and irradiated CDW32 L cells. In agreement with our results, no growth activity of IL-13 was observed on unstimulated or anti-mustimulated B-CLL cells.
Our study reveals a second point of discrepancy between the effects of IL-13 on normal and B-CLL cells. IL-13 significantly suppresses IL-2-induced proliferation of B-CLL cells, in contrast with previous data obtained in a few patients by Fluckiger et al." This effect is obtained with concentrations of IL-13 ranging from 10 to 200 ng/mL. The negative interaction between IL-13 and 1L-2 is observed in three experimental conditions: (1) when B-CLL cells spontaneously respond to IL-2, (2) when an optimal response is obtained with the combination of anti-mu antibody plus IL-2, and (3) when B-CLL cells are activated with both anti-CD40 MoAb and IL-2. In normal B cells, IL-13 potentiates the DNA synthesis elicited by IL-2 (Defrance et a16 and results not shown) and, more generally, exhibits a positive effect on the control of normal B-cell activation and differentiati~n.""'.~ However, a negative regulatory effect of IL-13 has recently been shown on the proliferation of normal B-cell precursors and their malignant counterparts in B-lineage acute lymphoblastic leukemia (BCP-ALL).33 Thus, IL-13, as does IL-4, can exert a dual effect on B-cell activation. Among the B-CLL cells tested, the great majority are inhibited by both IL-13 and IL-4, suggesting a general common mechanism for this inhibitory effect. However, in one patient, IL-4 induced B-cell proliferation with no effect of IL-13 (patient 7); in contrast, in one other patient, IL-13 inhibits IL-2-induced B-cell proliferation, whereas IL-4 is ineffective (patient 4).
This intriguing fact has been observed in only one patient and, until now, has had no clearcut explanation. Recent data show that the IL4R a chain is a functional component of the IL-13R" and our results would imply that these B-CLL cells express IL-13R but lack a functional IL-4R. In fact, the same B-CLL cells are able to proliferate when stimulated with anti-CD40 MoAb plus IL-4, suggesting that the IL4R is present on these cells but that the functional effects of IL-4 on B-CLL cells depend on the activation signal."
The precise mechanisms involved in the negative effect of IL-13 on B-CLL cells has not been fully explored in this work. However, it is important to note that the IL-l3 negative effect is restricted to IL-2-induced proliferation and is not observed when B In this report, we show that IL-13 partially inhibits spontaneous in vitro apoptosis of B-CLL cells. This effect is dose-dependent and is usually slightly less than that observed with IL-4 on the same B-CLL cells. Interestingly, IL-13-mediated prevention of in vitro apoptosis is observed with B-CLL cells expressing high or moderate sensitivity to spontaneous apoptosis or to tumor necrosis factor-induced apoptosis (results not shown). To our knowledge, this is the first report showing that IL-13 is a regulatory cytokine controlling apoptosis of cells of the immune system. Fluckiger et a137 have shown that IL-13 increased cell viability but did not find a protective effect of IL-13 on spontaneous apoptosis of B-CLL cells. However, they used a low dose of IL-13 (30 ng/mL), and only one of the five patients studied exhibited a spontaneous apoptosis. This apoptosis was measured on day 1. Clearly, in our hands, the protective effect of IL-13 was observed later (day 2 to day 6) and with higher doses (200 ng/mL).
Little is known about how T cells interact with malignant B cells in B-CLL. It is interesting to note that TH2-like cytokines may have a differential effect on the control of apoptosis of B-CLL cells: protecting (IL-4, IL-13) or enhancing (IL-10). These preliminary data do not explore the mechanisms of an IL-13 protective effect. Recently, it has been reported that the IL-4-mediated protection of in vitro BFor personal use only. on August 30, 2017. by guest www.bloodjournal.org From CLL cell apoptosis was associated with upregulation of Bcl-2 expression." However, Bcl-2-independent mechanisms of prevention of apoptosis have been described for other cell types and in neoplasic human B cells stimulated with anti-CD40 MoAb" or IFN-cY.'~ Using the experimental model of B-CLL cell cultures, we are currently studying the regulation by IL-13 of different molecules involved in apoptosis regulation, including Bcl-2, c-myc, fas, and p53. In vivo, by inhibiting cell proliferation and preventing apoptosis, IL-13 may contribute to the accumulation of slow-dividing and longlived monoclonal CD5+ B cells and may be involved in the pathogenesis of CLL.
